Dr. Suryadevara had her medical education at Osmania Medical College, her residency at the University of Nevada, School of Medicine and specialized in Oncology and Hematology with her fellowship at the University of New Mexico. She specialized in benign hematology, breast cancer and gynecologic cancer. She values building trusting relationships with her patients and considers it a privilege and solemn responsibility to be part of their advocacy team. She listens and not just hears her patients and open to negotiating goals of care.
Sutter Health Research Enterprise
2001 Dwight Way
Berkeley, CA, 94704
(510) 204-1591
suryadu@sutterhealth.org
Primary Research Interests
Related Clinical Trials
Commands
ACE-536 VS.Epoetin Alfa for the TX of Anemia Due to IPSS-R Very Low,Low or Intermediate Risk MDS in ESA Naïve Subjects Who Require RBC Transfusions
Investigators: Oleg I. Krijanovski M.D., Ph.D., Uma Suryadevara MD
Status: Active, Recruiting
Connect
Connect® MDS/AML Disease Registry
Investigators: Rajesh Behl M.D., Oleg I. Krijanovski M.D., Ph.D., Uma Suryadevara MD
Status: Active, Recruiting
Locally Advanced or Metastatic (Alliance A082002)
Testing the Addition of RT to the Usual Treatment (Immunotherapy +/- Chemotherapy) for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-L1 Negative
Investigator: Uma Suryadevara MD
Status: Active, Recruiting
Metastatic (Alliance A032001)
Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Trmt, Avelumab, in Pts With Metastatic Urothelial Cancer, MAIN-CAV Study
Investigator: Uma Suryadevara MD
Status: Active, Recruiting
Myelofibrosis (INCB 50465-304)
A Randomized, Double-Blind, Placebo-Controlled Study of the PI3Kd Inhibitor Parsaclisib Plus Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal
Investigators: Rajesh Behl M.D., Oleg I. Krijanovski M.D., Ph.D., Uma Suryadevara MD
Status: Active, Recruiting
Myelofibrosis (INCB 50465-313)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kd Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibros
Investigators: Rajesh Behl M.D., Oleg I. Krijanovski M.D., Ph.D., Uma Suryadevara MD
Status: Active, Recruiting